Familial Adenomatous Polyposis (FAP)

Also known as: Familial Adenomatous Polyposis / Adenomatous Polyposis Coli / Polyposis coli / Familial polyposis

DrugDrug NameDrug Description
DB00482Celecoxib_Celecoxib_ is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and is also used to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name _Celebrex_. Celecoxib is available by prescription in capsule form [A34124]. By inhibiting prostaglandin synthesis, non-steroidal anti-inflammatory drugs (NSAIDs) cause mucosal damage, ulceration and ulcer complication throughout the gastrointestinal tract. Celecoxib, however, poses less of an ulceration risk, owing to its decreased effect on gastric mucosal prostaglandin synthesis, when compared to placebo [A34152]. Interestingly, selective COX-2 inhibitors (especially _celecoxib_), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies [A34124].
DB00605SulindacSulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.
DrugDrug NamePhaseStatusCount
DB00482Celecoxib2Active Not Recruiting1
DB00482Celecoxib2Terminated1
DB11672Curcumin2Completed1
DB11672Curcumin2Withdrawn1
DB06243Eflornithine2Terminated1
DB00530Erlotinib2Recruiting1
DB00331Metformin2Recruiting1
DB00482Celecoxib2 / 3Completed1
DB01586Ursodeoxycholic acid2 / 3Completed1
DB06243Eflornithine3Active Not Recruiting1
DB06243Eflornithine3Withdrawn1
DB00605Sulindac3Active Not Recruiting1
DB00482Celecoxib4Terminated1
DB11672CurcuminNot AvailableCompleted1